E
OKUR

Ergoteles’s OnKure Therapeutics OKUR Stock Holding History

Ergoteles’s Portfolio OKUR Stock Details OKUR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-3,025
Closed -$70.5K – 1830
2022
Q4 		$70.5K Sell
3,025
-739
-20% -$19.6K ﹤0.01% 1263
2022
Q3 		$126K Sell
3,764
-476
-11% -$15.6K ﹤0.01% 1315
2022
Q2 		$112K Buy
+4,240
New +$98.7K ﹤0.01% 1474

Other funds holding OKUR

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
RVM
RiverVest Venture Management St. Louis, Missouri $6.84M AUM 7.71% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10B AUM 10.61% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ECM
ExodusPoint Capital Management New York $15.5B AUM 38.81% 1-Year Est. Return

Ergoteles's OKUR Position: Q1 2023 in Review

Ergoteles sold out of OnKure Therapeutics (OKUR) in Q1 2023, closing a stake of 3,025 shares — an estimated $70.5K sold.

Ergoteles first reported a position in OKUR in Q2 2022 and held it in 3 quarters. The position peaked at $126K in Q3 2022. 35 funds tracked by Wall St. Rank hold OKUR as of Q1 2023.

  • Ergoteles reported no remaining OnKure Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Ergoteles sold 3,025 OnKure Therapeutics shares in Q1 2023, an estimated $70.5K.
  • Ergoteles first reported a position in OnKure Therapeutics in Q2 2022 and held it in 3 quarters.
  • Ergoteles's OnKure Therapeutics position peaked at $126K in Q3 2022.
  • 35 funds tracked by Wall St. Rank held OnKure Therapeutics as of Q1 2023.

Based on Ergoteles's 13F filing for Q1 2023, filed 10 May 2023.